Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Portell, Craig A, Wenzell, Candice M, Advani, Anjali S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650887/
https://www.ncbi.nlm.nih.gov/pubmed/23671399
http://dx.doi.org/10.2147/CPAA.S42689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650887/
https://www.ncbi.nlm.nih.gov/pubmed/23671399
http://dx.doi.org/10.2147/CPAA.S42689

Ejemplares similares